Tavaborole Suppliers & Bulk Manufacturers
Available Forms: Topical Solution
Available Strengths: 5%
Reference Brands: Kerydin (USA/EU)
Category:
Anti-fungal
Tavaborole is available in Topical Solution
and strengths such as 5%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tavaborole is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tavaborole can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tavaborole is a topical antifungal medication sold under the brand name Kerydin, primarily used for the treatment of onychomycosis, a fungal infection affecting the nails and nail beds. It works by inhibiting leucyl-tRNA synthetase, an essential fungal enzyme required for protein synthesis. By blocking this enzyme, tavaborole disrupts protein production in fungal cells, leading to termination of cell growth and ultimately fungal cell death, effectively treating the infection.
In clinical trials, tavaborole demonstrated superior efficacy compared to its vehicle alone. It achieved complete clearance in approximately 6–7% of patients and partial clearance in 23–24% of cases, particularly in individuals where the infection did not extend to the cuticle at the base of the large toenail. The medication was approved by the US FDA in July 2014 and is applied directly to the affected nails once daily. Tavaborole offers a convenient, non-invasive treatment option for patients with mild to moderate onychomycosis, helping to eliminate fungal infections and improve nail health over time.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing